Trial Profile
A retrospective cohort study assessing efficacy and safety of dalbavancin as primary and sequential treatment of Gram-positive bacteremia with infective endocarditis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2018
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacteraemia; Bacterial endocarditis; Gram-positive infections
- Focus Therapeutic Use
- 25 Apr 2018 New trial record
- 05 Apr 2018 Results published in the Clinical Infectious Diseases